Related Experiment Video

Updated: Aug 8, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Distamycin-A derivatives potentiate tumor-necrosis-factor activity via the modulation of tyrosine phosphorylation

J P Zou1, I Nathan, A Dvilansky

  • 1Department of Hematology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

International Journal of Cancer
|September 25, 1997
PubMed

Insights

Novel distamycin-A derivatives, FCE 24517 and FCE 25450A, show cytotoxic effects and enhance tumor-necrosis factor-alpha (TNF) sensitivity. FCE 25450A synergizes with TNF by inhibiting protein phosphorylation, suggesting a new therapeutic mechanism.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cancer Research

Background:

  • Distamycin-A derivatives are novel cytotoxic agents.
  • Tumor-necrosis factor-alpha (TNF) is a key cytokine in inflammation and cell death.
  • Understanding drug combinations is crucial for cancer therapy.

Purpose of the Study:

  • To evaluate the cytotoxic activities of FCE 24517 and FCE 25450A.
  • To investigate the synergistic effects of these derivatives with TNF.
  • To elucidate the molecular mechanisms underlying the observed drug interactions.

Main Methods:

  • Cell culture of HL60, SV80, and L929 cell lines.
  • Dose-response studies for cytotoxic activity.
  • Sequential drug exposure experiments (distamycin derivatives followed by TNF).
  • Analysis of protein tyrosine phosphorylation and de-phosphorylation using Western blotting.
  • Inhibition studies with orthovanadate, a tyrosine-phosphatase inhibitor.

Main Results:

  • Both FCE 24517 and FCE 25450A exhibited dose-dependent growth inhibition of cancer and fibroblast cell lines.
  • FCE 25450A demonstrated significant synergistic anti-proliferative effects when combined sequentially with TNF in L929 cells.
  • FCE 25450A pre-treatment inhibited TNF-induced tyrosine phosphorylation of specific proteins and prevented de-phosphorylation, an effect reversed by orthovanadate.
  • Orthovanadate diminished the anti-proliferative action of the FCE 25450A/TNF combination.

Conclusions:

  • Distamycin-A derivatives, particularly FCE 25450A, possess cytotoxic properties and can enhance cellular sensitivity to TNF.
  • The synergistic effect appears to be mediated by the inhibition of TNF-induced tyrosine phosphorylation of proteins involved in TNF resistance.
  • Protein de-phosphorylation may represent an additional mechanism of action for these novel distamycin-A derivatives, offering potential for novel cancer therapeutics.

More Related Videos

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: